Aquestive Therapeutics (AQST) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$129.1 million.
- Aquestive Therapeutics' Enterprise Value fell 6569.27% to -$129.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.1 million, marking a year-over-year decrease of 6569.27%. This contributed to the annual value of -$71.5 million for FY2024, which is 19970.68% down from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Enterprise Value is -$129.1 million, which was down 6569.27% from -$60.5 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Enterprise Value high stood at -$14.7 million for Q1 2022, and its period low was -$129.1 million during Q3 2025.
- For the 5-year period, Aquestive Therapeutics' Enterprise Value averaged around -$46.8 million, with its median value being -$28.0 million (2021).
- As far as peak fluctuations go, Aquestive Therapeutics' Enterprise Value skyrocketed by 4831.16% in 2022, and later tumbled by 30056.16% in 2024.
- Over the past 5 years, Aquestive Therapeutics' Enterprise Value (Quarter) stood at -$28.0 million in 2021, then increased by 2.68% to -$27.3 million in 2022, then rose by 12.47% to -$23.9 million in 2023, then plummeted by 199.71% to -$71.5 million in 2024, then crashed by 80.39% to -$129.1 million in 2025.
- Its Enterprise Value was -$129.1 million in Q3 2025, compared to -$60.5 million in Q2 2025 and -$68.7 million in Q1 2025.